1. Home
  2. IPDN vs SNGX Comparison

IPDN vs SNGX Comparison

Compare IPDN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IPDN

Professional Diversity Network Inc.

HOLD

Current Price

$0.91

Market Cap

9.5M

Sector

Technology

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.15

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPDN
SNGX
Founded
2003
1987
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5M
11.2M
IPO Year
2012
2006

Fundamental Metrics

Financial Performance
Metric
IPDN
SNGX
Price
$0.91
$1.15
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
63.9K
173.5K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
$22,054,219.00
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$1.00
52 Week High
$12.39
$6.23

Technical Indicators

Market Signals
Indicator
IPDN
SNGX
Relative Strength Index (RSI) 32.25 44.93
Support Level N/A $1.01
Resistance Level $1.98 $1.47
Average True Range (ATR) 0.10 0.07
MACD -0.02 -0.00
Stochastic Oscillator 4.77 58.70

Price Performance

Historical Comparison
IPDN
SNGX

About IPDN Professional Diversity Network Inc.

Professional Diversity Network Inc provides access to networking, training, educational, and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates the majority of its revenue from the TalentAlly Network Segment.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: